Minnesota Oncology

Multiple Myeloma News

Velcade Approved for Retreatment in Multiple Myeloma (August 21, 2014)

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior... Continue Reading

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (August 7, 2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide)... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (July 22, 2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

Elotuzumab Earns U.S. Food and Drug Administration Breakthrough Therapy Designation for Multiple Myeloma (May 26, 2014)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the drug elotuzumab for use in previously treated, or relapsed, multiple myeloma. This announcement was recently made in a press release from drug-maker Bristol-Myers... Continue Reading

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma (March 10, 2014)

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a phase II study published in Blood. Multiple myeloma... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Revlimid After Stem Cell Transplantation Delays Progression of Myeloma, but Does Not Improve Overall Survival (February 24, 2014)

In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed cancer progression, but did not prolong overall survival.... Continue Reading

Continuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly Diagnosed Multiple Myeloma (December 12, 2013)

Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better overall survival than standard treatment with melphalan,... Continue Reading

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma (November 25, 2013)

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma, according to the results of a study published... Continue Reading

Panobinostat Plus Velcade and Dexamethasone Shows Promise in Heavily Pretreated Myeloma (November 18, 2013)

The experimental drug panobinostat (LBH-589) in combination with Velcade® (bortezomib) and dexamethasone is effective for heavily pretreated multiple myeloma, according to the final results from a phase 2 clinical trial published in Blood. Multiple myeloma... Continue Reading

Latest Multiple Myeloma News By Stage


Recurrent Multiple Myeloma

Velcade Approved for Retreatment in Multiple Myeloma (August 21, 2014)

The U.S. Food and Drug Administration (FDA) has approved Velcade® (bortezomib) for the retreatment of adult patients with multiple myeloma who had previously responded to Velcade therapy and relapsed at least six months following completion of prior... Continue Reading

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (August 7, 2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide)... Continue Reading

Elotuzumab Earns U.S. Food and Drug Administration Breakthrough Therapy Designation for Multiple Myeloma (May 26, 2014)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the drug elotuzumab for use in previously treated, or relapsed, multiple myeloma. This announcement was recently made in a press release from drug-maker Bristol-Myers... Continue Reading

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma (March 10, 2014)

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a phase II study published in Blood. Multiple myeloma... Continue Reading

Kyprolis/Revlimid/Dexamethasone Produces Durable Responses in Relapsed Multiple Myeloma (November 25, 2013)

The combination of Kyprolis® (carfilzomib), Revlimid® (lenalidomide), and low-dose dexamethasone was well tolerated and produced durable responses in patients with relapsed progressive multiple myeloma, according to the results of a study published... Continue Reading

More Recurrent Multiple Myeloma

Stage I/Smoldering Myeloma Multiple Myeloma

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Early Treatment of Multiple Myeloma Slows Progression (August 30, 2013)

Early treatment with Revlimid® (lenalidomide) and dexamethasone for patients with high-risk smoldering multiple myeloma delays progression to active disease and increases overall survival, according to the results of a study published in the New England... Continue Reading

Continuous Revlimid May Improve Outcomes in Newly Diagnosed Multiple Myeloma (December 15, 2010)

Among older patients with newly diagnosed multiple myeloma, treatment with Revlimid® (lenalidomide) in combination with melphalan and prednisone, followed by Revlimid maintenance therapy (MPR-R) may result in better progression-free survival than two... Continue Reading

Revlimid Maintenance Slows Myeloma Progression After Stem Cell Transplant (December 14, 2010)

Maintenance therapy with Revlimid® (lenalidomide) reduced the risk of myeloma progression or death by 60% among patients who had undergone an autologous stem cell transplant. These updated results from a Phase III clinical trial were presented at the... Continue Reading

Improved Survival with Zometa in Multiple Myeloma (December 14, 2010)

It appears that treatment of patients with newly diagnosed multiple myeloma with Zometa® (zoledronic acid) may improve overall survival and progression-free survival. These findings were recently reported in The Lancet. Multiple myeloma is a cancer of... Continue Reading

More Stage I/Smoldering Myeloma Multiple Myeloma

Stages II-III Multiple Myeloma

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (July 22, 2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

Treanda/Velcade/Dexamethasone Produces High Response Rate in Relapsed/Refractory Multiple Myeloma (March 10, 2014)

The combination of Treanda® (bendamustine), Velcade® (bortezomib) and dexamethasone produced a high response rate in patients with relapsed/refractory multiple myeloma, according to the results of a phase II study published in Blood. Multiple myeloma... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Revlimid After Stem Cell Transplantation Delays Progression of Myeloma, but Does Not Improve Overall Survival (February 24, 2014)

In a Phase III clinical trial among patients who had undergone stem cell transplantation for multiple myeloma, post-transplant maintenance therapy with Revlimid® (lenalidomide) significantly delayed cancer progression, but did not prolong overall survival.... Continue Reading

Continuous Revlimid/Lose-Dose Dexamethasone Improves Outcomes in Newly Diagnosed Multiple Myeloma (December 12, 2013)

Among people with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation, continuous treatment with Revlimid® (lenalidomide) and low-dose dexamethasone results in better overall survival than standard treatment with melphalan,... Continue Reading

More Stages II-III Multiple Myeloma